Peter Nielsen: Well, certainly ovarian, advanced ovarian has been one that we’ve worked along with. But the way the strategy for that trial, the 1- or /1b was to open the dose escalation portion because that’s monotherapy to pretty much all the solid tumors in that area. It’s faster. I mean, and we’re just looking for the safety evaluation. Then once you get to the 1b, that’s when you get, of course the specific types, so 1b in advanced ovarian and endometrial, a 1b in pancreatic, and a 1b in the triple negative cancer. And those are all, remember combination therapies. So you would use one combination to go across those. They’d all have their specific ones.
Yi Chen: Okay, Got it. Does the company currently have sufficient capital to fund operations to the point of starting the trial for BP1003?
Peter Nielsen: I believe so. I think that should be ready to go next year. That’s our goal. I think, as I mentioned last time we’re redoing the drug substance detection so that we can finish that last tox study in rabbits and we are remanufacturing or have pretty much remanufactured the drug for that get it off to the Charles River to finish that up. So, I mean, our goal certainly as we said in our releases and whatnot, is that should be in the first six months of next year. And once that happens we can get our IND filed. So, I believe that everything else is done, so and we have sufficient cash for the requirements of runway that was, we’ve noted the end of September and we just added that with a small strategic raise to make sure we kept that runway out there past October next year, so that we continue to demonstrate that viability. So
Yi Chen: Okay. Thank you.
Peter Nielsen: You’re welcome.
Operator: Thank you. And the next question comes from Laura Engel with Stonegate Capital Partners.
Laura Engel: Good morning. How are you?
Peter Nielsen: I’m doing well. How are you, Laura? Good to have you back.
Laura Engel: I’m good, thanks. Thanks. Yes, thanks for taking my call. So most of my questions have been answered, but you did mention discussions with partners and the strength of the patent portfolio. Any notable updates there, anything, any discussions that are progressed to the point you want to talk about it for therapeutic areas, either in cancer or even outside the realm of cancer?
Peter Nielsen: No, nothing. I think the only time we’d do something is if we actually had something concrete that had happened, and so we just, I don’t really think it’s too speculative to talk about people’s interests and whatnot. And there has been in the past, and for us it has to be the right time. I think past some of these things that are going on, starting at the end of the first quarter next year, may prompt some interest that could finalize. But I can’t be definitive on that right now. But our main focus recall is to be a company that develops these DNAbilize drug products that treat more difficult to treat patient’s diseases and some people will have interest in that. But our model is not to be a pharma company that would pull those into the commercialization.
